Cyclic RGD peptide analogues as antiplatelet antithrombotics.

  title={Cyclic RGD peptide analogues as antiplatelet antithrombotics.},
  author={P. Barker and S. Bullens and S. Bunting and D. Burdick and K. Chan and T. Deisher and C. Eigenbrot and T. Gadek and R. Gantzos and M. Lipari},
  journal={Journal of medicinal chemistry},
  volume={35 11},
  • P. Barker, S. Bullens, +7 authors M. Lipari
  • Published 1992
  • Chemistry, Medicine
  • Journal of medicinal chemistry
  • Stimulation of platelets activates GPIIbIIIa, the heterodimeric integrin receptor, to bind fibrinogen (Fg), which results in platelet aggregation. GPIIbIIIa/Fg binding inhibitors are potentially suitable for acute use during and after thrombolytic therapy as antithrombotic agents. Incorporation of the tripeptide sequence Arg-Gly-Asp (RGD), a common structural element of many integrin ligands, into cyclic peptides produced a series of peptides of the general structure BrAc-(AA1)-RGD-Cys-OH… CONTINUE READING
    134 Citations
    Antithrombotic agents: from RGD to peptide mimetics.
    • 102
    A novel series of orally active antiplatelet agents.
    • 21


    or an Applied Biosystems Inc. Model 431A or 433A peptide synthesizer. The peptides
    • J. Am. Chem. Soc.,
    • 1984
    After the initial coupling, the alpha-amino protecting group is removed
    • 1973
    incor porated herein by reference
    • Chem. Soc.,
    • 1963